Facebook
Twitter
LinkedIn
Forward
Obesity is one of the leading causes of the development of type 2 diabetes mellitus.
|
Insulin resistance (IR) is a common biochemical abnormality in patients with excess adiposity, obesity, and its complications.
|
Obesity is emerging as a serious and complex health condition affecting about 1 billion people in the world.
|
The number of non-nutritive sweeteners (NNS) available, both synthetic and natural, has increased rapidly in recent years.
|
Childhood obesity is a multifaceted health challenge.
|
Obesity pharmacotherapy often is solely equated as therapeutic use of anti-obesity medications (AOMs). In this session, two important factors in obesity pharmacotherapy will be discussed.
|
Poor responders to common medical weight loss treatments is a challenging situation for clinicians.
|
This talk will review key features of obesity pathogenesis related to genetics, the brain, and energetics.
|
An important part of the Obesity Medicine provider’s practice, and one of the pillars of obesity care, is considering the use of medications for the treatment of overweight and obesity. Anti-obesi
|
CME/CE Expiration Date: 6/29/2026* *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
|